Proteomics, as one ofthe disciplines ofthe 'omics' cascade (genomics, transcriptomics, proteomics and metabolomics), is projected to have a profound impact on the clinical practice of oncology in the coming decades. Recent advances in proteomics have been hallmarked by orders of magnitude Increases in speed and sensitivity. These advances are driving bioinformatics efforts to facilitate and automate data interpretation and integration into the 'omics' pipeline and application to translational medicine. The 'data gathering' technologies for proteomics now have a firm, quantitative foundation and are being widely applied to biomarker development and hypothesis generation in cancer research. The SCCC Proteomics Core supports cancer research for biomarker development (discovery, verification and validation) and global molecular Investigations into cancer mechanisms. Both gel based (2D-DIGE) and quantitative label-free proteomics are available to researchers, the latter using high-resolution hybrid mass spectrometers (FTICR-MS and LTQ-Orbitrap-XL), Consultation in experimental design, feasibility, statistics, and customized sample preparation for proteomics studies is provided by the Director, a Bioinformaticist, and Mass Spectrometrist. Standardized proteomic workflows are executed by a skilled staff of senior research technicians. Assistance with proteomics data analysis is provided using advanced software tools for both gel (DeCyder (DIA, BVA and EDA modules), MASCOT and SCAFFOLD ) and non-gel (Rosetta Elucidator , SORCERER-2 ) proteomics. The Core hosts greater than fifty terabytes of RAID array storage capacity for gel images, mass spectrographic, and meta data that have been acquired since the establishment of the Core in August, 2003. Since the last competitive renewal, the Core has worked with 58 SCCC members. The expertise and resources of the SCCC Proteomics Core are being applied to biomarker projects in pancreatic cancer (Dr. David Linehan), prostate cancer (Dr. Adam Kibel), breast cancer (Dr. Mathew Ellis), bladder cancer (Dr. Robert Grubb lllrd), cervical cancer (Dr. Janet Rader), and lung cancer (Dr. Issam El Naqa). In addition, the Core is currently supporting basic science projects in cell cycle regulation (Dr. Helen Piwnica Worms), mechanisms of CTL cell killing (Dr. Tim Ley), imaging apoptosis (Dr. David Piwnica-Worms), nucleoli proteomics and translational regulation (Dr. Jason Weber), telomere protein dynamics (Dr. Sheila Stewart), glycoprotein hormone (Dr. Jacques Baenziger), stromal contributions of glioma formation (Dr. Joshua Rubin), and molecular characterization of stage I lung cancer (Dr. Ming You). For biomarker development, customized immunometric services are provided which include both expertise and instrumentation to develop new assays for candidate protein biomarkers.

Public Health Relevance

The Proteomics Core provides the research community with the technology and expertise to discover new proteins for the eariy detection of cancer and to understand mechanisms of cancer at the molecular level. Proteins are the product of information encoded in human genome.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Saint Louis
United States
Zip Code
Zuiani, Adam; Chen, Kevin; Schwarz, Megan C et al. (2016) A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I. J Virol 90:10499-10512
Abboud, Ramzi; Keller, Jesse; Slade, Michael et al. (2016) Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. Biol Blood Marrow Transplant 22:1851-60
Johnson, Kimberly J; Zoellner, Nancy L; Gutmann, David H (2016) Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1. Cancer Epidemiol 42:53-9
Brownson, Ross C; Dodson, Elizabeth A; Kerner, Jon F et al. (2016) Framing research for state policymakers who place a priority on cancer. Cancer Causes Control 27:1035-41
Chou, Chun; Verbaro, Daniel J; Tonc, Elena et al. (2016) The Transcription Factor AP4 Mediates Resolution of Chronic Viral Infection through Amplification of Germinal Center B Cell Responses. Immunity 45:570-82
Durai, Vivek; Murphy, Kenneth M (2016) Functions of Murine Dendritic Cells. Immunity 45:719-736
Beeman, Scott C; Shui, Ying-Bo; Perez-Torres, Carlos J et al. (2016) O2 -sensitive MRI distinguishes brain tumor versus radiation necrosis in murine models. Magn Reson Med 75:2442-7
Mertins, Philipp; Mani, D R; Ruggles, Kelly V et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534:55-62
Niu, Haixia; Hadwiger, Gayla; Fujiwara, Hideji et al. (2016) Pathways of retinoid synthesis in mouse macrophages and bone marrow cells. J Leukoc Biol 99:797-810
Willet, Spencer G; Mills, Jason C (2016) Stomach Organ and Cell Lineage Differentiation: from Embryogenesis to Adult Homeostasis. Cell Mol Gastroenterol Hepatol 2:546-559

Showing the most recent 10 out of 947 publications